跳至主要内容
临床试验/KCT0007442
KCT0007442尚未招募未知

Prospective, multicenter, open-labeled, phase II study of clinical effect of the combination of metformin and standard chemotherapy in patient with newly diagnosed with T-cell lymphoma and the role of AMP-activated protein kinase (AMPK)

Kyungpook National University Hospital0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
20(Year) 至 70(Year)(—)
性别
All

入选标准

  • not applicable

排除标准

  • not applicable

研究者

相似试验

进行中(未招募)
不适用
A phase II, open-label, prospective, multicenter study to evaluate theefficacy and safety of subsequent treatment with the Zevalin(ibritumomab tiuxetan) study in patients with follicular grade I-IIlymphoma after 4 cycles of Fludarabine-Mitoxantrone-Rituximab(FMR) therapy. - ND
EUCTR2006-004850-26-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
进行中(未招募)
1 期
A phase II, multicentre, open label, prospective, interventional study to evaluate the sperm DNA fragmentation in idiopathic male infertility before and after treatment with Gonal-f PEN 900 IU. - NDIdiophatic male infertilityMedDRA version: 9.1Level: SOCClassification code 10014698
EUCTR2010-020196-23-ITMERCK SERONO SPA
进行中(未招募)
1 期
A study evaluating the safety and efficacy of the combination of tirabrutinib (GS-4059) and entospletinib with and without obinutuzumab in subjects with chronic lymphocytic leukemiaAdults with relapsed or refractory chronic lymphocytic leukemiaMedDRA version: 20.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864
EUCTR2016-002768-15-DEGilead Sciences, Inc.36
进行中(未招募)
1 期
A study evaluating the safety and efficacy of the combination of tirabrutinib (GS-4059) and idelalisib with and without obinutuzumab in subjects with chronic lymphocytic leukemia
EUCTR2015-003909-42-DEGilead Sciences, Inc.36
进行中(未招募)
不适用
Prospective, open label, multi center phase II clinical trial with neoadjuvant chemotherapy in addition with Sorafenib in patients with primarily advanced ovarian cancer (FIGO IIIC + IV) and ascites (>500ml) - primofenib-07Stage FIGO IIIc and IV with more than 500 ml ascitesMedDRA version: 9.1Level: LLTClassification code 10057529Term: Ovarian cancer metastaticOvarian Cancer
EUCTR2006-004644-24-DEniversity of Bonn102